Anti-CSF1R and anti-CCL2 blocking antibodies in combination with chemotherapy are in phase I/II clinical trials in pancreatic, breast, and liposarcoma cancers [65,66,67]. The gene discussed is CSF1R; the disease is liposarcoma.